Exact Sciences Posts Flat Q2 Revenues

The firm collected $1.3 million in licensing fees, as it continues development of its stool-based DNA test for colorectal cancer.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register here quickly for free access.

Related Stories